Patents by Inventor Andrew Bristol

Andrew Bristol has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Beta-lactamase formulations and uses thereof
    Patent number: 10828260
    Abstract: The present invention provides, in part, formulations comprising a beta-lactamase. Particularly, modified-release formulations comprising a beta-lactamase are provided which release a substantial amount of the beta-lactamase in the intestines. Therapeutic uses of the beta-lactamase formulations are also provided.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: November 10, 2020
    Assignee: Synthetic Biologics, Inc.
    Inventors: Andrew Bristol, Michael Kaleko, Sheila Connelly
  • RECOMBINANT MONOCLONAL ANTIBODIES AND CORRESPONDING ANTIGENS FOR COLON AND PANCREATIC CANCERS
    Publication number: 20200255535
    Abstract: The present invention provides for recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens, along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to the nucleic acids, and uses for these antibodies, nucleic acids and amino acids.
    Type: Application
    Filed: February 20, 2020
    Publication date: August 13, 2020
    Inventors: J. ANDREW BRISTOL, JUDITH A. KANTOR
  • BETA-LACTAMASE FORMULATIONS
    Publication number: 20200108130
    Abstract: The present invention provides, in part, formulations comprising a beta-lactamase. Particularly, modified-release powder formulations comprising a beta-lactamase are provided which release a substantial amount of the beta-lactamase in the intestines. Therapeutic uses of the beta-lactamase formulations are also provided.
    Type: Application
    Filed: March 20, 2018
    Publication date: April 9, 2020
    Inventors: Andrew BRISTOL, Klaus GOTTLIEB, J. Blair WEST
  • COLON AND PANCREAS CANCER SPECIFIC ANTIGENS AND ANTIBODIES
    Publication number: 20190322720
    Abstract: This invention relates to NPC-1 antigen on the MUC5AC protein and 16C3 antigen on CEACAM5 and CEACAM6 proteins, and 31.1 epitope on the A33 protein are differentially expressed in cancers including, lung cancer, ovarian cancer, pancreas cancer, breast cancer, and colon cancer, and diagnostic and therapeutic usages. Further, NPC-1, 16C3, and/or 31.1 epitope specific antibodies and diagnostic and therapeutic methods of use.
    Type: Application
    Filed: November 30, 2018
    Publication date: October 24, 2019
    Inventors: Xiulian DU, Janos LUKA, Lewis Joe STAFFORD, Mark Semenuk, Xue-Ping WANG, Judith KANTOR, Andrew BRISTOL
  • RECOMBINANT MONOCLONAL ANTIBODIES AND CORRESPONDING ANTIGENS FOR COLON AND PANCREATIC CANCERS
    Publication number: 20190322759
    Abstract: The present invention provides for purified or highly pure recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens (CPAA), along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to said nucleic acids and uses for said sequences.
    Type: Application
    Filed: June 12, 2019
    Publication date: October 24, 2019
    Inventors: Myron ARLEN, J. Andrew Bristol, Ariel Hollinshead, Kwong Tsang
  • Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
    Patent number: 10364295
    Abstract: Purified or highly pure recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens (CPAA), along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to said nucleic acids and uses for said sequences are provided.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: July 30, 2019
    Assignee: PRECISION BIOLOGICS, INC.
    Inventors: Myron Arlen, J. Andrew Bristol, Ariel Hollinshead, Kwong Tsang
  • BETA-LACTAMASE FORMULATIONS AND USES THEREOF
    Publication number: 20180360762
    Abstract: The present invention provides, in part, formulations comprising a beta-lactamase. Particularly, modified-release formulations comprising a beta-lactamase are provided which release a substantial amount of the beta-lactamase in the intestines. Therapeutic uses of the beta-lactamase formulations are also provided.
    Type: Application
    Filed: August 24, 2018
    Publication date: December 20, 2018
    Inventors: Andrew Bristol, Michael Kaleko, Sheila Connelly
  • RECOMBINANT MONOCLONAL ANTIBODIES AND CORRESPONDING ANTIGENS FOR COLON AND PANCREATIC CANCERS
    Publication number: 20180346594
    Abstract: The present invention provides for recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens, along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to the nucleic acids, and uses for these antibodies, nucleic acids and amino acids.
    Type: Application
    Filed: June 15, 2018
    Publication date: December 6, 2018
    Inventors: J. ANDREW BRISTOL, JUDITH A. KANTOR
  • Beta-lactamase formulations and uses thereof
    Patent number: 10105322
    Abstract: The present invention provides, in part, formulations comprising a beta-lactamase. Particularly, modified-release formulations comprising a beta-lactamase are provided which release a substantial amount of the beta-lactamase in the intestines. Therapeutic uses of the beta-lactamase formulations are also provided.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: October 23, 2018
    Assignee: SYNTHETIC BIOLOGICS, INC.
    Inventors: Andrew Bristol, Michael Kaleko, Sheila Connelly
  • Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
    Patent number: 10023650
    Abstract: The present invention provides for recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens, along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to the nucleic acids, and uses for these antibodies, nucleic acids and amino acids.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: July 17, 2018
    Assignee: PRECISION BIOLOGICS, INC.
    Inventors: J. Andrew Bristol, Judith A. Kantor
  • E. COLI-BASED PRODUCTION OF BETA-LACTAMASE
    Publication number: 20180030458
    Abstract: The invention relates to, in part, improved methods for the production of beta-lactamase using Escherichia coli (E. coli) cells. High yield production of beta-lactamase is achieved using methods of the invention.
    Type: Application
    Filed: August 27, 2015
    Publication date: February 1, 2018
    Inventors: Andrew BRISTOL, Michael KALEKO
  • RECOMBINANT MONOCLONAL ANTIBODIES AND CORRESPONDING ANTIGENS FOR COLON AND PANCREATIC CANCERS
    Publication number: 20170218080
    Abstract: The present invention provides for purified or highly pure recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens (CPAA), along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to said nucleic acids and uses for said sequences.
    Type: Application
    Filed: February 10, 2017
    Publication date: August 3, 2017
    Inventors: Myron ARLEN, J. Andrew Bristol, Ariel Hollinshead, Kwong Tsang
  • Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
    Patent number: 9605077
    Abstract: The present invention provides for purified or highly pure recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens (CPAA), along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to said nucleic acids and uses for said sequences.
    Type: Grant
    Filed: June 15, 2015
    Date of Patent: March 28, 2017
    Assignee: Precision Biologics, Inc.
    Inventors: Myron Arlen, J. Andrew Bristol, Ariel Hollinshead, Kwong Tsang
  • RECOMBINANT MONOCLONAL ANTIBODIES AND CORRESPONDING ANTIGENS FOR COLON AND PANCREATIC CANCERS
    Publication number: 20160326260
    Abstract: The present invention provides for recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens, along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to the nucleic acids, and uses for these antibodies, nucleic acids and amino acids.
    Type: Application
    Filed: May 19, 2016
    Publication date: November 10, 2016
    Inventors: J. Andrew BRISTOL, Judith A. Kantor
  • Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
    Patent number: 9371375
    Abstract: The present invention provides for recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens, along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to the nucleic acids, and uses for these antibodies, nucleic acids and amino acids.
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: June 21, 2016
    Assignee: Precision Biologics, Inc.
    Inventors: J. Andrew Bristol, Judith A. Kantor
  • BETA-LACTAMASE FORMULATIONS AND USES THEREOF
    Publication number: 20160101058
    Abstract: The present invention provides, in part, formulations comprising a beta-lactamase. Particularly, modified-release formulations comprising a beta-lactamase are provided which release a substantial amount of the beta-lactamase in the intestines. Therapeutic uses of the beta-lactamase formulations are also provided.
    Type: Application
    Filed: October 8, 2015
    Publication date: April 14, 2016
    Inventors: Andrew Bristol, Michael Kaleko, Sheila Connelly
  • RECOMBINANT MONOCLONAL ANTIBODIES AND CORRESPONDING ANTIGENS FOR COLON AND PANCREATIC CANCERS
    Publication number: 20150353644
    Abstract: The present invention provides for purified or highly pure recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens (CPAA), along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to said nucleic acids and uses for said sequences.
    Type: Application
    Filed: June 15, 2015
    Publication date: December 10, 2015
    Inventors: Myron Arlen, Andrew Bristol, Ariel Hollinshead, Kwong Tsang
  • Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
    Patent number: 9169326
    Abstract: The present invention provides for purified or highly pure recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens (CPAA), along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to said nucleic acids and uses for said sequences.
    Type: Grant
    Filed: January 24, 2011
    Date of Patent: October 27, 2015
    Assignee: PRECISION BIOLOGICS, INC.
    Inventors: Myron Arlen, J. Andrew Bristol, Ariel C. Hollinshead, Kwong Y. Tsang
  • RECOMBINANT MONOCLONAL ANTIBODIES AND CORRESPONDING ANTIGENS FOR COLON AND PANCREATIC CANCERS
    Publication number: 20140369926
    Abstract: The present invention provides for recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens, along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to the nucleic acids, and uses for these antibodies, nucleic acids and amino acids.
    Type: Application
    Filed: June 19, 2014
    Publication date: December 18, 2014
    Inventors: J. Andrew BRISTOL, Judith A. KANTOR
  • Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
    Patent number: 8802090
    Abstract: The present invention provides for recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens, along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to the nucleic acids, and uses for these antibodies, nucleic acids and amino acids.
    Type: Grant
    Filed: January 24, 2011
    Date of Patent: August 12, 2014
    Assignee: Precision Biologics, Inc.
    Inventors: J. Andrew Bristol, Judith A Kantor